Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis.

Abstract

OBJECTIVE:

We evaluated potential circulating biomarkers of disease activity in giant cell arteritis (GCA), Takayasu arteritis (TA), polyarteritis nodosa (PAN), and eosinophilic granulomatosis with polyangiitis (EGPA).

METHODS:

A panel of 22 serum proteins was tested in patients enrolled in the Vasculitis Clinical Research Consortium Longitudinal Studies of GCA, TA, PAN, or EGPA. Mixed models were used for most analyses. A J48 classification tree method was used to find the most relevant markers to differentiate between active and inactive GCA.

RESULTS:

Tests were done on 418 samples from 152 patients (60 GCA, 29 TA, 26 PAN, 37 EGPA), during both active vasculitis and remission. In GCA, these showed significant (p < 0.05) differences between disease states: B cell-attracting chemokine 1 (BCA)-1/CXC motif ligand 13 (CXCL13), erythrocyte sedimentation rate (ESR), interferon-γ-induced protein 10/CXC motif chemokine 10, soluble interleukin 2 receptor α (sIL-2Rα), and tissue inhibitor of metalloproteinase-1 (TIMP-1). In EGPA, these showed significant increases during active disease: granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage-CSF, interleukin (IL)-6, IL-15, and sIL-2Rα. BCA-1/CXCL13 also showed such increases, but only after adjustment for treatment. In PAN, ESR and matrix metalloprotease (MMP)-3 showed significant differences between disease states. Differences in biomarker levels between diseases were significant for 11 markers and were more striking (all p < 0.01) than differences related to disease activity. A combination of lower values of TIMP-1, IL-6, interferon-γ, and MMP-3 correctly classified 87% of samples with inactive GCA.

CONCLUSION:

We identified novel biomarkers of disease activity in GCA and EGPA. Differences of biomarker levels between diseases, independent of disease activity, were more apparent than differences related to disease activity. Further studies are needed to determine whether these serum proteins have potential for clinical use in distinguishing active disease from remission or in predicting longer-term outcomes.

• Authors: Alicia Rodriguez-Pla, Roscoe L Warner, David Cuthbertson, Simon Carette, Nader A Khalidi, Curry L Koening, Carol A Langford, Carol A McAlear, Larry W Moreland, Christian Pagnoux, Philip Seo, Ulrich Specks, Antoine G Sreih, Steven R Ytterberg, Kent J Johnson, Peter A Merkel, Paul A Monach, Vasculitis Clinical Research Consortium
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 47 Issue 7 Pg. 1001-1010 (07 01 2020) ISSN: 0315-162X [Print] Canada
• PMID: 31474593 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Tissue Inhibitor of Metalloproteinase-1

Topics

• Biomarkers
• Churg-Strauss Syndrome
• Giant Cell Arteritis (diagnosis)
• Granulomatosis with Polyangiitis
• Humans
• Tissue Inhibitor of Metalloproteinase-1